- Home
- ARGX vs RJF Comparison
ARGX vs RJF Comparison
Compare ARGX & RJF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARGX
- RJF
- Stock Information
- Founded
- ARGX 2008
- RJF 1962
- Country
- ARGX Netherlands
- RJF United States
- Employees
- ARGX N/A
- RJF N/A
- Industry
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- RJF Investment Bankers/Brokers/Service
- Sector
- ARGX Health Care
- RJF Finance
- Exchange
- ARGX Nasdaq
- RJF Nasdaq
- Market Cap
- ARGX 40.4B
- RJF 28.5B
- IPO Year
- ARGX 2017
- RJF N/A
- Fundamental
- Price
- ARGX $590.06
- RJF $130.26
- Analyst Decision
- ARGX Strong Buy
- RJF Buy
- Analyst Count
- ARGX 20
- RJF 12
- Target Price
- ARGX $682.00
- RJF $164.64
- AVG Volume (30 Days)
- ARGX 373.1K
- RJF 1.7M
- Earning Date
- ARGX 05-08-2025
- RJF 04-23-2025
- Dividend Yield
- ARGX N/A
- RJF 1.53%
- EPS Growth
- ARGX N/A
- RJF 28.28
- EPS
- ARGX 12.78
- RJF 10.24
- Revenue
- ARGX $2,248,205,000.00
- RJF $13,239,000,000.00
- Revenue This Year
- ARGX $57.86
- RJF $12.38
- Revenue Next Year
- ARGX $31.90
- RJF $7.00
- P/E Ratio
- ARGX $43.50
- RJF $12.73
- Revenue Growth
- ARGX 77.22
- RJF 12.75
- 52 Week Low
- ARGX $352.77
- RJF $104.24
- 52 Week High
- ARGX $678.21
- RJF $174.32
- Technical
- Relative Strength Index (RSI)
- ARGX 44.86
- RJF 30.82
- Support Level
- ARGX $565.00
- RJF $135.08
- Resistance Level
- ARGX $598.06
- RJF $142.40
- Average True Range (ATR)
- ARGX 14.20
- RJF 3.66
- MACD
- ARGX -0.77
- RJF -0.29
- Stochastic Oscillator
- ARGX 40.42
- RJF 0.84
Stock Price Comparison Chart: ARGX vs RJF
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
About RJF Raymond James Financial Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company supports more than 8,000 employee and independent contractor financial advisors across the United States, Canada, and the United Kingdom with over $1.5 trillion of assets under administration as of September 2024. Approximately 90% of the company's revenue is from the US and 70% is from the company's wealth-management segment.